Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis
Metrics: HTML 1299 views | ?
Hui Li1,*, Dongwen Wu2,*, Shupeng Shi2, Yadong Xu2, Ling Wei2, Jing Liu2 and Yanting Liu2
1Reproductive Department, Xiangya Hospital, Central South University, Changsha, China
2Xiangya School of Medicine, Central South University, Changsha, China
*These authors have contributed equally to this work
Hui Li, email: HUILI257@hotmail.com
Keywords: renal cell carcinoma, CD147, case control study, meta-analysis
Received: September 26, 2016 Accepted: February 21, 2017 Published: April 10, 2017
Objective: To assess clinical significance of CD147 in renal cell carcinoma.
Methods: Collect case-control studies which focus on CD147’s expression in renal cell carcinoma. Trails were retrieved from CBM, CNKI, Wan-fang database, PubMed, Cochrane Library and Embase. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently, and outcomes were pooled with Revman5.3 and STATA14.0.
Results: A total of 11 studies were confirmed, among which renal cell carcinoma 887 cases, non-cancer 505cases. As for the positive rate of CD147, there are statistical differences among survival, renal cell carcinoma tissue vs. non-cancer tissues [OR= 8.19, P= 0.0002], with vs. without lymph node metastases [OR= 6.52, P= 0.001], clinical stage III~IV vs. II~I [OR= 4.07, P< 0.00001], histopathological stage III~IV vs. II [OR= 3.01, P= 0.002], histopathological stage III~IV vs. I [OR= 7.50, P< 0.00001], tumor size [OR= 5.01, P= 0.0007]. No significant difference was tested among different age, gender, histological types and Position of cancer.
Conclusion: As shown in our results, CD 147 may participate the whole course of carcinogenesis of renal cell carcinoma, which might be valuable for the diagnosis, treatment and prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.